...
首页> 外文期刊>The journal of gene medicine >CBS gene polymorphism and promoter methylation-mediating effects on the efficacy of folate therapy in patients with hyperhomocysteinemia
【24h】

CBS gene polymorphism and promoter methylation-mediating effects on the efficacy of folate therapy in patients with hyperhomocysteinemia

机译:CBS基因多态性和启动子甲基化 - 培养介质对高管症患者叶酸治疗患者的疗效

获取原文
获取原文并翻译 | 示例

摘要

Background A decrease in cystathionine beta-synthase (CBS) enzyme activity could lead to hyperhomocysteinemia (HHcy). Studies have revealed that DNA methylation has a mediating effect on the development of diseases. The present study aimed to explore CBS promoter methylation-mediating effects on the efficacy of folate treatment for HHcy. Methods HHcy patients were treated with folate (5 mg/day) for 90 days and then divided into a failure group (Hcy >= 15 mu mol/l) and a success group (Hcy < 15 mu mol/l) according to post-treatment plasma Hcy levels. Genotyping of CBS gene (rs2851391 and rs706209) in patients (n = 638) was detected using a MassArray system (Sequenom, San Diego, CA, USA). The baseline DNA methylation levels of patients (n = 299) were detected using MethylTarget (TM) technology (Genesky Biotechnologies Inc., Shanghai, China). Results The CBS rs2851391 TC + CC genotype was related to a 57% reduction of failure risk in HHcy treatment compared to the TT genotype (95% confidence interval [CI] = 0.19-0.97). The CBS rs706209 CT + TT genotype had a 2.97-fold increased risk of failure to treatment compared to the CC genotype (95% CI = 1.52-5.80). After adjustment for confounding factors, the odds ratio (95% CI) for the risk of failure in HHcy treatment in total and male patients was 0.55 (0.32-0.93) and 0.34 (0.16-0.69), respectively, for patients with higher methylation levels (>= methylation median). Additionally, baseline CBS promoter methylation mediated 33.39% of the effect of rs2851391 on the efficacy of folate treatment for HHcy (ACME [average causal mediation effects]: -0.05, 95% CI = -0.11 to 0.00, p = 0.046). Conclusions The present study indicates that CBS gene polymorphism and promoter methylation could affect the efficacy of HHcy. There were potentially causal effects of genetic, epigenetic variations at the CBS rs2851391 locus on the efficacy of HHcy therapy with folate.
机译:背景胱硫胺β-合酶(CBS)酶活性的减少可能导致过量囊肿(HHCy)。研究表明,DNA甲基化对疾病的发育具有介质效果。本研究旨在探讨CBS启动子甲基化介导对Hhcy叶酸治疗疗效的影响。方法将HHCY患者用叶酸(5mg /天)处理90天,然后分为失效组(Hcy> =15μmol/ L),并根据后的成功组(Hcy <15μmol/ L)。治疗血浆Hcy水平。使用MassArray系统(Sequenom,San Diego,Ca,USA)检测患者CBS基因(RS2851391和RS706209)的CBS基因(RS2851391和RS706209)的基因分型。使用甲基靶(TM)技术(Genesky Biotechnologies Inc.,Shanghai,China)检测患者基线DNA甲基化水平(N = 299)。结果CBS RS2851391 TC + CC基因型与HHCY治疗中的失败风险降低57%有关(95%置信区间[CI] = 0.19-0.97)。与CC基因型相比(95%CI = 1.52-5.80)相比,CBS RS706209 CT + TT基因型的患者的失败风险增加2.97倍。在调整混淆因素后,总共和男性患者的HHCY治疗失败风险的差距(95%CI)分别为甲基化水平较高的患者,分别为0.55(0.32-0.93)和0.34(0.16-0.69) (> =甲基化中值)。此外,基线CBS启动子甲基化介导33.39%的RS2851391对HHCE(ACME [平均因果调解作用]:-0.05,95%CI = -0.11至0.00,P = 0.046)的叶酸治疗效果的33.39%。结论本研究表明,CBS基因多态性和启动子甲基化可能影响HHCY的功效。 CBS RS2851391基因座的遗传,表观遗传变异有潜在的因果作用,叶酸Hhcy疗法的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号